Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO, Jan. 1, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026.

SAN FRANCISCO, Dec. 31, 2025 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026.

SAN FRANCISCO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026.

Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing SAN FRANCISCO , Dec. 27, 2025 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026.

SAN FRANCISCO, Dec. 25, 2025 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026.

Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO , Dec. 24, 2025 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026.

Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.

Corient Private Wealth LLC grew its stake in shares of Charles River Laboratories International, Inc. (NYSE: CRL) by 129.3% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,825 shares of the medical research company's stock after

SAN FRANCISCO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026.

Are There Red Flags in the Trial Results?